Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Invested Capital (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Return on Invested Capital for 4 consecutive years, with 0.88% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Invested Capital fell 48.0% year-over-year to 0.88%, compared with a TTM value of 0.88% through Sep 2025, down 48.0%, and an annual FY2024 reading of 0.43%, down 5.0% over the prior year.
  • Return on Invested Capital was 0.88% for Q3 2025 at Barinthus Biotherapeutics, down from 0.7% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.02% in Q3 2022 and bottomed at 0.88% in Q3 2025.
  • Average Return on Invested Capital over 4 years is 0.35%, with a median of 0.41% recorded in 2023.
  • The sharpest move saw Return on Invested Capital increased 1bps in 2024, then crashed -48bps in 2025.
  • Year by year, Return on Invested Capital stood at 0.16% in 2022, then plummeted by -162bps to 0.42% in 2023, then dropped by -11bps to 0.47% in 2024, then crashed by -87bps to 0.88% in 2025.
  • Business Quant data shows Return on Invested Capital for BRNS at 0.88% in Q3 2025, 0.7% in Q2 2025, and 0.58% in Q1 2025.